Early Feasibility Study of the Nervive VitalFlow Stimulation for Acute Ischemic Stroke Patients

Not Applicable

Withdrawn

• Conditions: Acute Stroke

• Registration Number: NCT04801225
• Lead Sponsor: Nervive, Inc.

Brief Summary

This Early Feasibility Study (EFS) is a multi-center, open-label single-arm study in 10 acute ischemic stroke (AIS) patients treated with VitalFlow-IS stimulation within 6 hours of symptom onset. The purpose of the EFS is to evaluate initial clinical safety and device functionality in the clinical workflow setting for treatment of acute ischemic stroke patients that will inform design modifications and/or user interface in preparation for next steps consisting of (1) a full safety/feasibility clinical study and (2) randomized controlled pivotal trial with a surrogate endpoint (expedited Premarket Approval (PMA) pathway).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-03-04
• Study First Submitted QC: 2021-03-13
• Study First Posted: 2021-03-16
• Study Start: 2022-08-24
• Status Verified: 2025-04
• Primary Completion: 2025-04-15
• Study Completion: 2025-04-15
• Last Update Submitted: 2025-04-15
• Last Update Posted: 2025-04-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Time last known normal within 4.5 hours of presentation for enrollment

  • Allows 1.5 hours for pre-stimulation study procedures to maintain a 6-hour therapeutic window
  • IV rtPA and Endovascular Treatment (EVT) permissible if not inappropriately delayed by study procedures

• Age 18-85 years

• Diagnosis of ischemic stroke in the anterior circulation

• NIHSS at baseline 4-20

• Creatinine < 1.7 mg/dL

• Signed informed consent by patient/Legally Authorized Representative (LAR)

Exclusion Criteria

• Pre-stroke disability Modified Rankin Score (mRS) between 2-6

• Inability to communicate sufficiently to participate in study procedures

• Neuroimaging with intracranial hemorrhage, severe brain edema, or ASPECTS <5

• Known or newly-discovered aneurysm or arteriovenous malformation (AVM)

• Intracranial mass lesion, infection, or other reason to suspect increased intracranial pressure

• Metallic foreign bodies or implanted devices in the head or neck, including tattoos

• Cardiac, vagal nerve, or intracranial neural stimulation device

• Cochlear implant or implanted hearing aid

• Potential for delay in intravenous rtPA or endovascular therapy due to study procedures

  • Intravenous (IV) rtPA: Stimulation might be delivered during the rtPA infusion period
  • EVT: Stimulation might be performed while EVT team is mobilized

• Seizure concurrent to stroke, or history of seizures, epilepsy, or recurrent syncopal events.

• History of neuropathy (including facial nerve injury), carotid surgery, or vagotomy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Feasibility of device use in the Clinical Environment as assessed by User Survey	1-7 days post-procedure	To demonstrate feasibility, device must have been able to be setup, deployed, and administer treatment without significant difficulty for each study subject, as recorded by the Investigator on the User Survey.
Rate of device-related adverse events	90 days post-procedure	Rate of device-related adverse events

Secondary Outcome Measures

Name	Time	Method
Exploratory - Rate of change in penumbra volume as measured by Computed Tomography Perfusion	2-4 hours post-procedure	Change in penumbra volume as measured by CTP at pre-stimulation vs 2-4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Difference in baseline core volume on CTP compared to 24 hour MRI final infarct volume	24 hours post-procedure	Difference in baseline core volume on CTP compared to 24 hour MRI final infarct volume. Being evaluated for potential use as surrogates in future studies.
Exploratory - Change in National Institute of Health Stroke Scale (NIHSS) - 24 hours	24 hours post-procedure	Change in NIHSS score \[range: 1-42, with lower score indicating better outcome\] pre-stimulation to 24 hours post-stimulation, and every 30 minutes up to 4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Patient Outcome as determined by Modified Rankin Scale (mRS)	90 days post-procedure	mRS score \[range: 0-6, with lower score indicating better outcome\] at 90 days post-procedure. Being evaluated for potential use as surrogates in future studies.
Exploratory - Rate of change in collateral blood flow as measured by Computed Tomography Perfusion	2-4 hours post-procedure	Change in collateral blood flow as measured by CTP at pre-stimulation vs 2-4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Rate of change in occlusion status as measured by Computed Tomography Perfusion	2-4 hours post-procedure	Change in occlusion status as measured by CTP at pre-stimulation vs 2-4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Patient Outcome as determined by National Institute of Health Stroke Scale (NIHSS)	90 days post-procedure	NIHSS score \[range: 1-42, with lower score indicating better outcome\] at 90 days post-procedure. Being evaluated for potential use as surrogates in future studies.
Exploratory - Rate of change in core volume as measured by Computed Tomography Perfusion	2-4 hours post-procedure	Change in core volumes as measured by CTP at pre-stimulation vs 2-4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Change in National Institute of Health Stroke Scale (NIHSS) - short-term	Pre-procedure, immediately post-procedure, 30, 60, 90, 120, 150, 180, 210, 240 minutes post-procedure	Change in NIHSS score \[range: 1-42, with lower score indicating better outcome\] pre to post-stimulation, and every 30 minutes up to 4 hours post-stimulation. Being evaluated for potential use as surrogates in future studies.
Exploratory - Final change in infarct growth - CTP (CBF<30%) at pre-stimulation vs MRI-DWI lesion at 24 hours	24 hours post-procedure	Final change in infarct growth - CTP (CBF\<30%) at pre-stimulation vs MRI-DWI lesion at 24 hours. Being evaluated for potential use as surrogates in future studies.

Trial Locations

Locations (2)

MetroHealth; 🇺🇸 Cleveland, Ohio, United States

The Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States